Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study
CONCLUSION: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.PMID:37245449 | DOI:10.1016/j.ejpn.2023.05.001 (Source: European Journal of Paediatric Neurology)
Source: European Journal of Paediatric Neurology - May 28, 2023 Category: Neurology Authors: Anne-Charlotte Saponaro Thomas Tully Elisabeth Maillart H élène Maurey Kumaran Deiva KidBiosep cohort study Source Type: research
Comparative adherence trajectories of oral disease ‐modifying agents in multiple sclerosis
ConclusionTeriflunomide and DMF were associated with poorer adherence trajectories than FIN. More research is needed to evaluate the clinical implications of these adherence trajectories of oral DMAs to optimize the management of MS. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 22, 2023 Category: Drugs & Pharmacology Authors: Jagadeswara Rao Earla,
Jieni Li,
George J. Hutton,
Michael L. Johnson,
Rajender R. Aparasu Tags: RESEARCH ARTICLE Source Type: research
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy
Discussion
Relapses during pregnancy after fingolimod cessation are common. Approximately 6% of women will retain clinically meaningful disability from these pregnancy-related, fingolimod cessation relapses 1 year postpartum. This information should be shared with women on fingolimod desiring pregnancy, and optimizing MS treatment with nonteratogenic approaches should be discussed. (Source: Neurology Neuroimmunology and Neuroinflammation)
Source: Neurology Neuroimmunology and Neuroinflammation - May 22, 2023 Category: Neurology Authors: Hellwig, K., Tokic, M., Thiel, S., Hemat, S., Timmesfeld, N., Ciplea, A. I., Gold, R., Langer-Gould, A. M. Tags: Multiple sclerosis Research Article Source Type: research
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing –Remitting Multiple Sclerosis in the United States
ConclusionTreatment with ozanimod was associated with substantial reductions in annual drug costs and total MS-related healthcare costs to avoid relapses compared with other DMTs. In the fixed-budget analysis, ozanimod demonstrated a favorable cost-effective profile relative to other DMTs. (Source: Neurology and Therapy)
Source: Neurology and Therapy - May 18, 2023 Category: Neurology Source Type: research
Influence of exercise on quantity and deformability of immune cells in multiple sclerosis
ConclusionPeople with multiple sclerosis (PwMS) treated with alemtuzumab, fingolimod, and natalizumab respond to acute exercise with a comparable temporal pattern characterized by the increase of immune cell subsets as HCs. The magnitude of response is influenced by exercise intensity. Exercise-mediated effects should be considered when interpreting laboratory values in patients on immunomodulatory therapy. The impact of exercise on biophysical properties should be further elucidated. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - May 18, 2023 Category: Neurology Source Type: research
Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
ConclusionIf proven to have translational value, these observations would suggest thatCNS/bloodDER may be a key differentiator for siponimod over fingolimod for clinical efficacy in PMS. (Source: Neurology and Therapy)
Source: Neurology and Therapy - May 17, 2023 Category: Neurology Source Type: research
Mode of binding, kinetic and thermodynamic properties of a lipid-like drug (Fingolimod) interacting with Human Serum Albumin
Conclusion: The pharmacokinetic properties of fingolimod can be influenced by its HSA binding. In addition, considering its mild interaction, site II binding drugs are likely to compete. The methodology described here may be used to investigate the molecular mechanism of HSA interaction with lipid-like drugs with low aqueous solubility or pH-dependent solubility.PMID:37193080 | PMC:PMC10182447 | DOI:10.34172/bi.2022.23383 (Source: BioImpacts)
Source: BioImpacts - May 16, 2023 Category: Research Authors: Samira Gholizadeh Hossein Haghaei Hosna Karami Somaieh Soltani Mostafa Zakariazadeh Javad Shokri Source Type: research
